LENVATINIB and VOMITING

Overview

VOMITING is the #8 most commonly reported adverse reaction for LENVATINIB, manufactured by Eisai Inc.. There are 1,880 FDA adverse event reports linking LENVATINIB to VOMITING. This represents approximately 2.9% of all 64,104 adverse event reports for this drug.

Patients taking LENVATINIB who experience vomiting should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

VOMITING is a less commonly reported adverse event for LENVATINIB, but still significant enough to appear in the safety profile.

Other Side Effects of LENVATINIB

In addition to vomiting, the following adverse reactions have been reported for LENVATINIB:

• DIARRHOEA — 3,869 reports
• HYPERTENSION — 3,419 reports
• FATIGUE — 3,124 reports
• DECREASED APPETITE — 2,970 reports
• NAUSEA — 2,312 reports
• MALIGNANT NEOPLASM PROGRESSION — 2,165 reports
• BLOOD PRESSURE INCREASED — 2,011 reports
• ASTHENIA — 1,534 reports
• DEHYDRATION — 1,460 reports
• WEIGHT DECREASED — 1,366 reports

Other Drugs Associated with VOMITING

The following drugs have also been linked to vomiting in FDA adverse event reports:

Does LENVATINIB cause VOMITING?

VOMITING has been reported as an adverse event in 1,880 FDA reports for LENVATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is VOMITING with LENVATINIB?

VOMITING accounts for approximately 2.9% of all adverse event reports for LENVATINIB, making it a notable side effect.

What should I do if I experience VOMITING while taking LENVATINIB?

If you experience vomiting while taking LENVATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages